Indication
Central Nervous System Malignancies
1 clinical trial
1 product
2 drugs
Clinical trial
Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS MalignanciesStatus: Not yet recruiting, Estimated PCD: 2027-07-01
Drug
T-VECDrug
DocetaxelProduct
5-Azacytidine